EBS — Emergent BioSolutions Inc.
EBS dilution and offerings
- Active shelf: S-3 (Aug 2025)
- Float: 50.3M shares
$6.44-5.43%
Last close: · regular session
After-hours $5.32 -17.36% ·
Last 60 sessions
Active shelf registration (S-3, Aug 2025). Float: 50.3M shares. Latest SEC filing: 8-K on Oct 16, 2026. EBS closed at $6.44 (-5.43%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for EBS in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
- Exchange: NYSE
- Employees: 900
- Website: https://www.emergentbiosolutions.com
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Latest SEC filings for EBS
Latest EBS news
- Emergent outlines $600M-$645M 2026 revenue outlook while raising adjusted gross margin to 45%-47% Read article
- Emergent Biosolutions Non-GAAP EPS of -$0.36 beats by $0.03, revenue of $110M misses by $13.2M Read article
- Emergent BioSolutions CFO Richard Lindahl to retire, Frank Vargo named interim CFO Read article
- Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock? Read article
- Emergent Biosolutions (NYSE:EBS) Stock: Insider Paul Anthony Williams Sells 3,000 Shares Read article
- Emergent Biosolutions Inc. (NYSE:EBS) Stock Has Consensus Price Target of $10.00 Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.